- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
Cediranib (AZD2171) is an orally active anticancer agent and a highly potent ATP-competitive receptor tyrosine kinase (RTK) inhibitor against VEGFR (IC50 = 5 nM/Flt-1 (VEGFR1), <1 nM/KDR (VEGFR2), ≤3 nM/Flt-4 (VEGFR3), c-Kit (IC50 = 2 nM), PDGFR1/2 (IC50 = 5/36 nM), and FGFR1 (IC50 = 26 nM). Cediranib exhibits reduced activity against CSF-1R, Src, Abl (IC50 = 110, 130, 260 nM, respectively) and little or no potency toward Flt-3, EGFR, ErbB2 (Her-2/neu), CDK2/4, Aurora A/B, and MEK.
Orally active anticancer agent, highly potent ATP-competitive tyrosine kinase inhibitor against VEGFR1/2/3 (Flt-1/KDR/Flt-4), c-Kit, PDGFR1/2 & FGFR1.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | 2-8°C |
| SMILES string | Fc1c2c([nH]c(c2)C)ccc1Oc3ncnc4c3cc(c(c4)OCCCN5CCCC5)OC |
| InChI | 1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 |
| InChI key | XXJWYDDUDKYVKI-UHFFFAOYSA-N |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
¥ 1148.92
-
¥ 2528.88
-
¥ 1596.77
-
¥ 2814.26
-
¥ 3109.49
-
询价
-
询价
-
询价
-
询价
-
¥ 1724.25
-
询价
-
¥ 5725.45
-
¥ 14407.09
-
询价
-
¥ 1564.00
-
¥ 1196.00
-
¥ 1586.69
-
¥ 2132.12
-
¥ 2288.54
-
询价
微信小程序
7X24小时在线咨询